Drafter's Name: Kevin L. Klette, DDRP

Releasers Info: Dr. Jo Ann Rooney, Acting USD(P&R)

UNCLASSIFIED

ACTION PRECEDENCE: Routine

FROM: SECDEF WASHINGTON DC

TO: ALDODACT

SUBJECT: Initiation of Expanded Prescription Drug Urinalysis Testing

In approximately 90 days, the Department of Defense (DoD) will expand military drug testing of the more commonly abused prescription drugs. While these powerful pain management drugs can alleviate suffering from injuries, they are potentially highly addictive and their use outside of medical supervision places the military members and their comrades at risk. Service members who are using prescription drugs that have not been prescribed or given by their health care provider are encouraged to voluntarily seek medical treatment and rehabilitation for themselves in a military medical treatment facility on a self-referral basis prior to the initiation of testing for these drugs.

Our DoD and Military Department policies state that individuals who do not self-refer for treatment and are subsequently identified as positive for controlled substances for which they do not have a valid prescription may be considered in violation of the Uniform Code of Military Justice for drug misuse/abuse. Prescription drugs are inappropriately used when they are used outside their intended purpose, beyond their prescribed dates, in excess of the prescribed dosing regimen, or when a Service member uses another individual's prescribed medications. Military members seeking substance use counseling can talk to their doctor, chain of command or self-refer to the substance abuse programs in their Service.

In addition, Military OneSource has contracted civilian counselors that provide confidential assessment and counseling to military personnel and their families. Military OneSource can be contacted at 1-800-342-9647, or though the Web at www.militaryonesource.com/MOS/About/CounselingServices.aspx.



OFFICE OF THE UNDER SECRETARY OF DEFENSE

4000 DEFENSE PENTAGON WASHINGTON, D.C. 20301-4000

ACTION MEMO

FOR: EXECUTIVE SECRETARY OF THE DEPARTMENT OF DEFENSE

FROM: Joseph J. Angello, Jr., Director, Operational Readiness and Safety

SUBJECT: Initiation of Expanded Prescription Drug Urinalysis Testing

- Request the Executive Secretary release the ALDODACT message (TAB A) on behalf of the Acting Under Secretary of Defense for Personnel and Readiness (USD (P&R)). The USD (P&R) approval of the message is at TAB B.
- We staffed this message with the Military Departments and at the Chairman of Joint Chiefs of Staff (CJCS) Tank on August 15, 2011, and are prepared to move forward with this initiative.
- The Department is expanding prescription drug testing to address the emerging threat in the force. As this initiative affects all active duty and reserve military members, the CJCS recommends and USD (P&R) supports a 90 day notification to all our military members.
- Due to expected media interest, it is our intent that this announcement has a coordinated release date with OSD (PA) and a notification to Congress. The ALDODACT message needs to be released as soon as possible.
- A one word change was made to the ALDODACT message to make it gender neutral.
- The Acting USD (P&R) signed the DoD Prescription Drug Implementation Plan, Response to Inquiries on Execution and Oversight in Protection of Service Members on Prescription Medications on January 26, 2012.

RECOMMENDATI	ON: Release the 90-day notice	e at TAB A to all DoD activities on
as soon as possible.	Approve Disappro	te at TAB A to all DoD activities on ove Other
	1/30/	

COORDINATION: TAB Michael L. Bruhn Executive Secretary Department of Defense

Attachments: As stated

Prepared by: CAPT Kevin Klette, Director, Drug Testing and Program Policy, 703-693-5230

PERSONNEL AND READINESS

OFFICE OF THE UNDER SECRETARY OF DEFENSE

4000 DEFENSE PENTAGON WASHINGTON, D.C. 20301-4000

ACTION MEMO

November 8, 2011

For: Jo Ann Rooney, Acting Under Secretary of Defense (Personnel and Readiness)

From: Laura J. Junor, Deputy Assistant Secretary of Defense (Readiness)

SUBJECT: 90-Day Notification Memorandum-Initiation of Expanded Prescription Drug Urinalysis Testing

- The purpose of this action memo is to provide a 90-day notice to all military personnel of the expansion of the DoD prescription drug testing panel of tested drugs (Tab A).
- While opiates are highly effective for pain management from traumatic war injuries or noncombat related injuries and benzodiazepines are beneficial for treatment of anxiety and stress disorders, they are highly addictive and subject to abuse.
- Prevalence of prescription misuse studies conducted by the Drug Demand Reduction Program demonstrates that large numbers of service members are abusing or misusing these drugs.
- According to a 2008 Department of Defense survey, 11-12% active duty military personnel reported past month illicit drug use, largely driven by the misuse of prescription drugs.
- The above data and other factors prompted the Chairman, Joint Chiefs of Staff (CJCS) to request (Tab B), and the Under Secretary of Defense for Personnel and Readiness (USD(P&R)) to approve (Tab C), the expansion of prescription drug testing to address the increased threat to military personnel.
- To ensure "Fairness and Compassion", the attached 90-day notification message of the new testing encourages individuals who may have developed drug dependency or drug addiction to seek drug counseling and treatment prior to launch of the new testing regimen.
- This message also compliments actions to be initiated by the Public Affairs Office in media wide news coverage of the expanded DDRP.

RECOMMENDATION:	You approve the 90 Pre-All DoD Activity message by signing at TAB A
	Approve Disapprove
COOPDINATION: TAI	NOV 1 8 2011

COORDINATION: TAB D

Attachments: As stated

Prepared by: CAPT Kevin Klette, Director, Drug Testing and Program Policy, 703-693-5230